Welcome to our dedicated page for Centene Del SEC filings (Ticker: CNC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Centene Corporation (NYSE: CNC) SEC filings, offering insight into the company’s regulatory disclosures, financial communications, and governance updates. As a healthcare enterprise focused on government-sponsored and commercial healthcare programs, Centene uses filings such as Form 8-K to inform investors about material events, earnings information, and board changes.
Recent 8-K filings describe Centene’s participation in healthcare investor conferences, where management discusses the company’s financial outlook and the use of non-GAAP financial measures like adjusted diluted earnings per share. Other 8-Ks report quarterly financial results, the withdrawal or update of earnings guidance, and the resignation of directors along with resulting changes in the size of the board. These documents help investors understand how Centene evaluates its performance, plans operations, and manages corporate governance.
Through this filings page, users can review Centene’s current and historical submissions to the U.S. Securities and Exchange Commission, including annual and quarterly reports when available, as well as event-driven filings. Real-time updates from EDGAR are combined with AI-powered summaries that explain the key points of complex documents, helping readers interpret financial metrics, non-GAAP reconciliations, and narrative disclosures without wading through every page.
In addition to financial information, Centene’s filings may address topics such as regulatory considerations, risk factors related to government healthcare programs, and the company’s approach to non-GAAP reporting. For investors tracking CNC, this page serves as a central location to monitor new filings, understand the context of earnings announcements, and follow changes in leadership or guidance as they are formally reported to the SEC.
Centene Corporation’s Chief Operating Officer, Susan Raye Smith, received an equity award of 112,823 shares of common stock on January 26, 2026. The grant was reported at a price of $0 per share and increased her beneficial ownership to 225,289 shares.
The award consists of 45,129 restricted stock units that vest in three annual installments beginning March 15, 2027, and 67,694 performance stock units reported at target. The performance stock units are scheduled to vest on March 15, 2029, with the actual number earned ranging from 0% to 200% of the target amount, based on Centene’s stock price performance between the final 20 trading days of 2025 and the final 60 trading days of 2028. Her total includes 90,117 previously granted restricted and performance stock units that remain subject to vesting requirements.
Centene Corporation granted Chief People Officer Tanya M. McNally 74,311 shares of common stock as equity compensation on January 26, 2026 at a price of $0 per share. Following this award, she beneficially owns 133,080 shares directly.
The new grant consists of 29,724 restricted stock units that vest in three annual installments beginning on March 15, 2027, and 44,587 performance stock units reported at target. The performance stock units can vest from 0% to 200% of target on March 15, 2029 based on Centene’s stock price performance over specified trading-day periods in 2025 and 2028. Existing ownership also includes 49,340 previously granted restricted and performance stock units that remain subject to vesting.
Centene Corporation CEO Sarah London received a large equity grant reported on January 26, 2026. She was awarded 520,720 shares of Centene common stock at a grant price of $0, bringing her directly owned common stock to 1,365,995 shares.
The award includes 138,859 restricted stock units vesting in three annual installments beginning March 15, 2027, and 69,429 restricted stock units vesting in five annual installments beginning the same date. It also includes 312,432 performance stock units at target; the actual amount vesting on March 15, 2029 can range from 0% to 200% of that target based on Centene’s stock price performance over specified trading-day periods in 2025 and 2028.
Her ownership also reflects 591,998 previously granted restricted and performance stock units that remain subject to vesting. In addition, she directly holds a performance stock option for 13,449 shares at an exercise price of $81.85 per share, expiring December 15, 2031, which may become exercisable if Centene’s stock trades at or above $100 for 20 consecutive trading days after the original grant date.
Centene Corporation’s Secretary & General Counsel, Christopher Koster, reported an equity compensation grant and updated holdings. On January 26, 2026, he was awarded 126,925 shares of common stock at $0 per share, reflecting restricted stock units and performance stock units subject to future vesting.
Following this grant, Koster beneficially owns 388,861.617 shares of Centene common stock directly and 100 shares indirectly through his spouse. He also holds a performance stock option for 15,690 shares at an exercise price of $81.85 that may become exercisable if a share price hurdle is met, plus 3,015.544 phantom stock units settled in cash or other non‑company securities upon termination or an elected date.
Centene Corporation reported an equity grant to Corporate Controller & CAO Katie Casso. On January 26, 2026, she was awarded 26,036 shares of common stock at a price of $0, reflecting compensation rather than an open-market purchase.
The grant consists of 13,018 restricted stock units that vest in three annual installments beginning on March 15, 2027, and 13,018 performance stock units that may vest on March 15, 2029, from 0% to 200% of target based on Centene’s stock price performance between late 2025 and late 2028. After this award, Casso beneficially owns 122,371 shares, including 62,561 previously granted restricted and performance stock units that remain subject to vesting.
Centene Corporation’s Chief Financial Officer, Asher Andrew Lynn, reported an equity award of 173,573 shares of common stock on January 26, 2026, at a price of $0 per share. This grant brings his directly held beneficial ownership of Centene common stock to 831,215.48 shares.
The award includes 69,429 restricted stock units that vest in three annual installments beginning March 15, 2027, and 104,144 performance stock units reported at target, which may vest on March 15, 2029 from 0% to 200% of target based on stock price performance tests. He also holds 13,449 performance stock options with a $81.85 exercise price expiring December 15, 2031, which become exercisable only if Centene’s stock trades at or above $100 for 20 consecutive trading days after the December 15, 2021 grant date.
Centene Corp’s Chief People Officer, Tanya M. McNally, reported a routine tax-related share transaction. On 01/15/2026, 725 shares of Centene common stock were withheld at a price of $46.17 per share to cover taxes due on the vesting of a previously reported grant of restricted stock units. After this withholding, she beneficially owns 58,769 shares of Centene common stock, which includes 49,340 shares in the form of previously granted restricted stock units and performance stock units reported at target performance and still subject to vesting requirements.
Centene Corporation director reports a routine stock grant. On 12/31/2025, the reporting person acquired 790 shares of Centene common stock at a price of $0, indicating an award rather than an open-market purchase.
After this grant, the director beneficially owned 6,738 shares of Centene common stock in direct ownership. The filing also explains that this total includes 3,579 shares of restricted stock units that are subject to vesting requirements, meaning some shares will only be fully owned if those conditions are met.
Centene Corp director updates equity ownership in a routine insider filing. On 12/31/2025, the director acquired 608 shares of Centene common stock at a reported price of $0, likely reflecting a grant rather than an open-market purchase. Following this transaction, the director beneficially owns 19,812.979 shares directly, including 3,579 restricted stock units that are subject to vesting requirements, and 32,000 shares held indirectly through a revocable family trust where he serves as co‑trustee.
The filing also lists a stock option giving the right to buy 10,000 shares of Centene common stock at an exercise price of $80.57, exercisable from 02/07/2025 until 02/07/2032, with all 10,000 derivative securities currently reported as beneficially owned.
Centene Corp director Christopher A. Koster reported acquiring 608 shares of Centene common stock on 12/31/2025 at a price of $0 per share. Following this transaction, he beneficially owned 360,360.658 shares of Centene common stock in total. The filing notes that this ownership includes 5,965 shares of restricted stock units that are subject to vesting requirements. The securities are held in direct ownership form.
FAQ
What is the current stock price of Centene Del (CNC)?
What is the market cap of Centene Del (CNC)?
